

**Information on Search Strategy - Pilot phase (see OJ 2015, A86)**

The type of information contained in this sheet may change during the pilot for improving the usefulness of this new service.

Application Number

PCT/EP2018/071478

TITLE: GLP-1/GLUCAGON RECEPTOR AGONISTS IN THE TREATMENT OF FATTY LIVER DISEASE AND STEATOHEPATITIS

APPLICANT: SANOFI

IPC CLASSIFICATION: A61K38/22, A61K38/26, A61P1/16

EXAMINER: Rodrigo-Simón, Ana

CONSULTED DATABASES: NPL, BIOSIS, MEDLINE, WPI

CLASSIFICATION SYMBOLS DEFINING EXTENT OF THE SEARCH:

IPC:

CPC: A61K38/2278, A61K38/26

FI/F-TERMS:

KEYWORDS OR OTHER ELEMENTS FEATURING THE INVENTION:

The present application is directed to dual GLP-1/glucagon receptor agonists of Formula A as claimed and therapeutic use such as preventing and/or treating metabolic liver disease, non-alcoholic fatty liver disease (NAFLD), particularly non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH) and/or NAFLD-associated liver fibrosis, liver cirrhosis and/or hepatocellular carcinoma, simultaneously preventing and/or simultaneously treating NASH and additional pathological conditions or risk factors, particularly obesity and/or type 2 diabetes mellitus.